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CHAPTER 1: INTRODUCTION 
 
 Malaria is an infectious parasitic disease that continues to be a global health threat.  
Malaria is a major cause of morbidity and mortality, particularly in children under 5 years old,  
in subtropical regions of the world. To understand the mechanisms of immunopathogenesis 
during disease may help the development of immunomodulatory therapeutics and vaccines.  This 
introduction is written to set the foundation for the following chapters based on this dissertation’s 
hypothesis:  CD4+ T-cell derived IL-10 mitigates anemia during malaria infection.  
Malaria: World impact 
 
Symptoms of malaria have been described as early as 2700 BC in Chinese medical 
literature (12).  The origin of the modern name ‘malaria’ stems from the Italian term for the 
disease: “mala aria’. ‘Mala aria’, which translates to ‘bad air’ in English, comes from the miasma 
theory of disease where disease is thought to be caused by toxins in the air.  The miasma theory 
was displaced by the germ theory, the idea that microorganisms cause disease, when the malaria 
parasite was identified in infected blood by Charles Lavern in 1880 (10).  
 Malaria, an infectious disease caused by parasites in the genus Plasmodia, remains a 
significant global health threat with the potential to infect over 3.3 billion people worldwide (1).  
Malaria is transmitted by the Anopheles mosquito and the vector is primarily found in tropical 
and subtropical regions, such as sub-Saharan Africa and Southeast Asia which coincide with 
areas the disease is found. The World Health Organization (WHO) reported in 2011 that malaria 
was present in IJZ!countries and an estimated 216 million cases of malaria were reported with 
655,000 deaths were due to the disease (1).  91% of these deaths occurred in Africa and the 
majority of these deaths (86%) were children under 5 years old (1).   
! T!
 Economically, malaria decreases the national gross domestic product (GDP) in high 
transmission countries by an estimated 1.3% (1).  In practical terms, the accumulated economic 
impact of malaria in high transmission countries has resulted in significantly lower GDP as 
compared to countries without malaria (1).  Since many of the affected countries are already 
economically depressed, the decrease in GDP further sets these countries at a disadvantage.    
 Malaria can also be found outside endemic areas due to international travel to affected 
regions.  There were 1688 reported cases of imported malaria in the US during 2010, which was 
a 14% increase over the number of 2009 cases (56). Approximately 400 people self-reported to 
have adhered to CDC recommended chemoprophylactic treatment for malaria, yet became 
infected, indicating suboptimal prophylaxis efficacy (56). In a study focusing on the number of 
imported cases of malaria in non-endemic industrialized countries from 1985 – 1995, 10,000 
cases were estimated to be imported annually (64).  Although the imported malaria cases 
comprise a very small percentage of the total number of cases worldwide, travelers are often 
susceptible to serious morbidity and mortality due to absent immunity to the disease (92, 100). 


















































































































































































































































Literature review relevant to Chapter 2 






























































A. Degree of anemia is disproportionately high though parasite is controlled in 


























Figure 2.1  Parasitemia and anemia during P. yoelii infection of IL-10 KO and B6 
mice.  IL-10 KO and B6 mice were given the same dose of parasite: IJZ!infected red 
blood cells, 5 mice/group.  Anemia and parasitemia were followed for 14 days. (A) 
Parasitemia was significantly lower in the IL-10 KO mice. (B) RBC numbers were 
similar between the two mouse groups: B6 (open circle) and IL-10 KO (filled circle) 
mice. Differences in parasitemia between both mouse groups were statistically 
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Table 2.1 Ratio of maximum red blood cell change divided by the 
maximum parasitemia in 4 individual experiments.  Ratio calculate by: 
("RBC count/106)/(%Parasitized RBC).  A higher value indicates greater 
anemia experienced relative to parasitemia.  *All differencd between B6 and 
IL-10 KO mice were significant p < 0.05 using a one tailed t test. 
! I\!
B. Greater anemia experienced in the absence of IL-10 when parasitemia is equivalent 



























C. IL-10 deficiency-associated RBC loss is due to a combination of suppressed 













Figure 2.2: IL-10 KO mice experience greater anemia relative to B6 mice when 
parasitemia is normalized. B6 (open circle) and IL-10 KO (filled circle). 104 and 107 
infected red blood cells given to B6 and IL-10 KO respectively, 5 mice/group. (A) 
Similar levels of parasitemia were achieved when IL-10 KO mice were infected with 
1000x the dose of parasite given to B6 mice (p = 0.6). (B) IL-10 KO mice developed 



















Figure 2.3: B6 and IL-10 KO mice make equivalent amounts of epo in response to 
anemia.  B6 (open circle) and IL-10 KO mice (filled circle) were infected and sacrificed 
at day 14 post infection. Data pooled from two separate experiments (5 
mice/group/experiment). The RBC count at day 14 (A) and day 10 (B) was plotted 
against the amount of epo detected in the serum on day 14.  Linear regression analysis 
demonstrated that in all cases the slope was identical between B6 and IL-10 KO mice.  
















Figure 2.4: Erythropoiesis.  Different erythropoietic stages of mice and humans 
(Figure adapted from (98)).  Although the figure above depicts early events of 
erythropoiesis in the bone marrow, erythropoiesis in the spleen, the primary murine 
erythropoietic organ during malaria infection, is similar.  CD71, a transferrin receptor, is 
expressed at high levels starting at the CFU-E stage of erythropoiesis and gradually 
declines and is largely absent on the mature RBC.  Ter119 is present beginning during 












































Figure 2.5 IL-10 KO mice experience greater degree of suppressed erythropoiesis. (A) 
The numbers of TER-119+ cells in the bone marrow of uninfected (N) and infected mice (Inf) 
were enumerated on day 14 post infection. Data pooled from two separate experiments (5 
mice/group/experiment). B6 (white) and IL-10 KO (dark grey) mice. (B) Number of TER-119+ 
cells relative to RBC loss (C) Representative dot plots showing the different maturation 
stages assessed.  (D) Number of splenic RBC precursors at different maturation stages for 
B6 (white) and IL-10 KO (dark grey) mice. (E) Proportion of Annexin-V+ cells within each 









































Figure 2.6:  Red blood cells are cleared at similar rates in both strains despite a 
markedly different degree of parasitemia. CFSE experiments reflect 5 
mice/group/infection (A) Kinetics of clearance of red blood cells in uninfected mice.  5 x 
108 CFSE labeled RBC from B6 mice were transferred into uninfected B6 and IL-10 KO 
mice.  The total number of CFSE+ red blood cells the next day were considered 100%, 
and the percentage of cells remaining each subsequent time point was calculated.  (B) B6 
and IL-10 KO mice were infected with 106 infected RBCs and treated with pyrimethamine 
starting at day 15 (broken arrow) for three days.  CFSE labeled red blood cells were 
transferred at day 17 (solid arrow), and (C) the relative percent of CFSE-labeled RBC 
clearance calculated as above indicate similar levels.  (D) RBC counts after IL-10 KO 
mice were infected with 1000x the dose of parasite given to B6 mice.  IL-10 KO mice 
were significantly more anemic on D7. Arrow points to day of CFSE transfer. (E) Relative 
percent of CFSE-labeled RBC was significantly lower in IL-10 KO mice on days 7 and 9 


















Figure 2.7:  Amount of RBC-associated antibodies is similar in both 
strains despite a markedly different degree of parasitemia.  
Antibodies on the surface of red blood cells appear during infection and 
are similar in both strains.  The amount of IgG on red blood cells was 
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CHAPTER 3: IL-10 DERIVED FROM TH1 CD4+ T-CELLS IS 



























Literature review relevant to Chapter 3 






























































8, CD4+ T-cells that arise during infection ameliorate anemia, but not parasitemia 
!
Since CD4+ T-cells from mice that have recovered from malaria make higher levels of 
IL-10, and IL-10 KO mice experience greater anemia, we hypothesized that these IL-10 
producing T-cells would protect from anemia.  To test this, CD4+ T-cells from P. yoelii 
infected/recovered (I/R) or naïve B6 mice were purified and transferred to athymic nude mice.  
We chose to use a T-cell deficient model with a full complement of B cells (rather than RAG 
knockout mice) in order to specifically test the effect of CD4+ T-cell manipulation in the 
presence of an otherwise functioning immune system. One day after CD4+ T-cell transfer, the 
recipients were infected with 1 x 106 parasitized red blood cells (RBCs).  This experiment was 
conducted three times.  Figure 3.2 shows the development of anemia and parasitemia of recipient 
! ^]!
mice in one experiment. The nude mice receiving T-cells from infected/recovered B6 mice (I/R 
CD4) developed a higher degree of parasitemia on days 9 and 12 post infection, yet anemia was 
not different as compared to nude mice that received T-cells from naïve B6 mice (Figure 3.2).  In 
order to quantify and compare the relationships between anemia and parasitemia between the 
different mouse groups, we measured the ratio between the maximum decrease in red blood cell 
count and the maximum degree of parasitemia during days 0 to 15 days post infection: [bq'$(!
56-*9iIJYcibgQ.3.0"9"P4+!'$(cw (Table 3.1).  A higher number indicates that the mouse is 
experiencing a greater degree of anemia relative to the parasite burden.   The degree of anemia 
relative to parasitemia was significantly greater in the naïve CD4+ T-cell nude mouse recipients 
in all three experiments.  These data suggest that CD4+ T-cells arise during infection and protect 
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Table 3.1: Ratio of maximum red blood cell change divided by the 
maximum parasitemia in 3 individual experiments. A higher value indicates 
greater anemia experience relative to parasitemia.  *All differences between 
nB6 CD4+ and I/R B6 CD4+ T-cell recipient nude mice were significant.  





















Figure 3.3:  Production of IL-10 and IFN-!  during P. yoelii infection.  (A) CD4+44hi T-cells 
produce the majority of IL-10 and IFN-! at day 15 PI (as well as day 30, not shown).  Spleen 
cells were stained with CD4 and CD44, and the CD4+, CD44 low and CD4+, CD44 high 
populations examined for IL-10 and IFN-! production after stimulation with PMA/ionomycin 
and brefeldin.  The panel labeled “competitor” depicts cells that were incubated with unlabeled 
anti-IL-10 and anti-IFN-! at 5x the dose of the fluorochrome labeled antibody before the 
fluorochrome labeled antibody was added.  This is used instead of isotype controls to 
determine the amount of non-specific staining.   (B) Cells were stained with anti-IL-10, anti-
IFN-! and anti-T-bet.  T-bet production was measured on each lymphocyte subset.  IFN-! 
producers, and IFN-!/IL-10 producers had identical levels of T-bet, but IL-10 producers had 
low levels.  (C) The distribution of cytokine producing cells at day 30 post infection reveals that 
the proportion of IL-10 secreting cells increased, but the majority of these cells also produced 
IFN-!.  The chart depicts the percentage of each type of cell in the CD4+CD44high population 
after stimulation with PMA/ionomycin with the top two and bottom two charts represent two 














`U!63!$Z!2"54!@434!93.*084334+!96!*-+4!2"54!.*+!9B4*!"*84594+!with 1 x 106 parasitized red 
blood cells (pRBCs)A!!&B4!4<743"24*9!@.0!56*+-594+!9@"54A!Figure 3.4 shows the development 








Figure 3.4:  Levels of Foxp3 remained constant throughout infection.  
The number of CD4+foxp3+ cells in the spleen are equal between Naïve (light 
grey) and Infected  (dark grey) mice. (A) Cells from naïve or 15 days post 
infection were stained with CD4 and examined for foxp3 production after 
stimulation with PMA/ionomycin and brefeldin. (B) Naive or 30 days post 






















Figure 3.5:  T-cells from infected/recovered IL-10 KO mice result in 
decreased parasitemia but a relatively greater degree of anemia 
compared with B6 mice.  (A) Nude mice were given 5 x 106 CD4 T-cells IP 
from B6 mice infected 30 days previously (white symbols) or  IL-10 KO mice 
(gray symbols) and infected the next day.  (B) Degree of parasitemia was 











































Table 3.2: Ratio of maximum red blood cell change divided by the 
maximum parasitemia for B6 and IL-10 KO mice in 2 individual 
experiments. A higher value indicates greater anemia experience relative to 
parasitemia.  *All differences between B6 CD4+ and 10KO CD4+ T-cell 
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Table 3.3: Comparison of integrated mean fluorescence intensity of CD4-derived 
IFN-! production between infected B6 and IL-10 KO mice (two different 
experiments: 1 and 2), and between nude mice receiving B6 or IL-10 KO CD4 T-
cells (exp. 3 and 4).  
*Experiments 1 and 2 are measurements of IFN-! production by T-cells at day 12 post 
infection.  Experiments 3 and 4 are measurements of IFN-! production by T-cells from 
infected/recovered B6 and IL-10KO mice 12 days after transfer into, and infection of, 
nude mice. 
†None = 4 hours of culture with brefeldin A and no stimulus, PMA = 4 hours of culture 
with brefeldin A, PMA, and ionomycin. 
‡Number indicates integrated mean fluorescence intensity:  (% of spleen cells that are 
CD4+CD44hiIFN-! x the mean fluorescence intensity of these cells /100). 






























































































Materials and Methods 
 
Mice and experimental infection 
C57BL/6J (B6), B6.129P2-Il10tm1Cgn/J (IL-10 KO), and B6.Cg-Foxn1nu/J (nude) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME) and used after a 2-wk 
acclimation period.  Mice were housed in the Painter Center, Colorado State University (Fort 
! YI!
Collins, CO), and all experiments were approved by the Institutional Animal Care and Use 
Committee.  P. yoelii 17X was used as described previously (74).   
 
'4+!>/66+!54//!.*+!7.3.0"94!56-*90!!
Anemia during infection was assessed by adding 2 ul blood obtained by tail nick to 998 
ul of PBS with 2% FBS.  50 ul of this solution was added to IJZ!Caltag counting beads to 
quantify red blood cell numbers, and the remainder was used for flow cytometric determination 
of parasitemia and reticulocyte counts.  Naïve mice were simultaneously evaluated to ensure that 





In order to quantify the degree of anemia relative to parasite burden, we calculated the 
maximum decrease in red blood cell count (pre-infection RBC count – RBC count on each day 
of infection), and the maximum percent parasitemia as determined by flow cytometry.  The ratio 
of these numbers (max RBC change/max parasitemia) is high if a small parasite burden causes 
substantial anemia, and comparatively low if it takes a greater parasite burden to cause the same 
degree of anemia.  
 
Cell surface markers 
Surface staining of cells include antibodies to CD4, CD44, CD45, Ter-119, and CD71 
(BD Biosciences).  Non-specific antibody binding was blocked using CD16/32 anti-mouse 
! YT!
antibodies (Fc block) prior to surface staining.  Immunofluorescence was detected as described 
above. 
 
Intracellular cytokines   
Splenocytes were stimulated for 4 hours with PMA (50ng/ml) and ionomycin (0.5ug/ml) 
in the presence of brefeldin A (10ug/ml) and 2ME (50uM) in DMEM-5% FBS.  Cells were 
surface stained, fixed in 4% paraformaldehyde for 20 minutes, and then permeabilized with 0.1% 
saponin in PBS.  Cells were then stained with anti-mouse IFN-!, IL-10, and T-bet antibodies 
(BD Biosciences) in .1% saponin.  Cells were treated with 10 ug/ml of anti CD32 prior to 
antibody staining to prevent non-specific binding.  Specificity of intracellular cytokines was 
confirmed using unlabeled antibody as a cold competitor how much?  How long?.  
Immunofluorescence was detected as described above. 
 
CD4+ T-cell transfer 
CD4+ T-cells were positively selected from mouse spleens using directly conjugated 
anti-CD4 microbeads (Miltenyi).  Because a significant amount of iron-containing pigment sticks 
non-specifically to magnetic columns, spleen cells were passed through a col umn before being 
incubated with the anti-CD4 beads.  Purification was then conducted according to the 
manufacturer and purity was >90%.  5xIJZ! CD4+ T-cells were transferred intraperitoneally per 









CHAPTER 4: IL-10 INDUCED IN TH1 CD4+ T-CELLS BY 



















Literature review relevant to Chapter 4 









































































A. P. yoelii exposed antigen presenting cells (APC), but not naïve APCs, induces IL-10 




















Figure 4.1: Ex vivo OTII assay to test APC function.  CD4+ T-cells 
from OTII mice, which encode ovalbumin-specific T-cells, are co-cultured 
with APCs from experimental mice in the presence of free ovalbumin.  
Cells are cultured for 5 days, then restimluated with PMA for 4 hours.  















































Figure 4.2 P. yoelli exposed APCs increase the development of IL-10/IFNg 
producing CD4+ T-cells.  (A) Comparing CD4+ T-cells that only produce IL-10 to 
those that produce both IL-10 and IFNg in the presence of naïve (N) or parasite 
exposed (Inf) APCs.  The majority of IL-10 producing CD4+ T-cells also produced 
IFNg, however there was a significantly greater percentage of IL-10+IFNg+ CD4+T-
cells in the presence of exposed APCs.  (B) keep the font and designation 
consistent only producing CD4+ T-cells did not differ in the presence of naïve vs. 
exposed APCs.  (C)  Levels of IL10+IFNg+ CD4+ T-cells in the presence of naïve 
vs. exposed APCs in three independent experiments.  3 mice per group were 
combined for APC enrichment and each condition was performed in triplicate in all 























Figure 4.3: P. yoelli exposed IL-10 KO and B6 APCs increase similar levels 
of IL-10/IFN! producing CD4+ T-cells.  Comparing CD4+ T-cells that express 
both IL-10 and IFN! in the presence of naïve or parasite exposed B6 or IL-10 
KO APCs.  Similar results in three independent experiments. 3 naïve and 5 
infected (day 3 post infection) B6 and IL-10KO mice were combined for APC 
enrichment and each condition was performed in triplicate in all experiments.  
















Figure 4.4: Ifn-! and IL-10 antibody consistently reduces IL-10 and Ifn-! 
expressing T-cell population. The effect of antibodies against IL-12, IL-10, and 
Ifn-! on T-cell IL-10 and Ifn-! expression.  (A, B, C) Comparing cytokine effect on 
CD4+ T-cells that express both IL-10 and IFN! in the presence of parasite 
exposed B6 APCs. (D,E, F) Comparing cytokine effect on CD4+ T-cells that 
express IFNg alone in the presence of parasite exposed B6 APCs. 3 naïve and 5 
infected (day 3 post infection) B6 and IL-10KO mice were combined for APC 
enrichment and each condition was performed in triplicate in all experiments.  
*p < .05, paired t test 
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Figure 4.5: Ifn-! antibody consistently reduces IL-10 expression relative to 
Ifn-! in T-cells. The effect of antibodies against IL-12, IL-10, and Ifn-! on T-cell 
IL-10 expression relative to Ifn-!.  (A, B, C) Comparing cytokine effect on CD4+ 
T-cells that express both IL-10 and IFN-! in the presence of parasite exposed 
B6 APCs. 5 infected B6 mice (day 3 post infection) were combined for APC 
enrichment and used for each condition which was performed in triplicate.  
*p < .05, paired t test 
 














Figure 4.6: Disrupting Notch pathway does not affect IL-10 in T-cells. The 
effect of blocking Notch receptor binding as well as activation was achieved with 
anti-DLL4 antibody or gamma secretase inhibitor (GSI).  A, B) Comparing two 
different Notch pathway disruptions on IL-10 expression in CD4+ T-cells in the 
presence of parasite exposed B6 APCs. C,D) Comparing Notch pathway 
disruption on CD4+ T-cells that express IFN! alone in the presence of parasite 
exposed B6 APCs.  The experiment was conducted twice and subfigures A/C 
and B/D are from the same experiment. 5 infected B6 mice (day 3 post infection) 
were combined for APC enrichment and used for each condition which was 


































































































CD4+ T-cell and APC enrichment  
 OTII CD4+ T-cells were positively selected from single cell suspension spleens using 
directly conjugated anti-CD4 microbeads according to manufacturer (Miltenyi). Likewise, APCs 
from experimental mice were enriched with directly conjugated anti-CDllc microbeads 
! [J!
(Miltenyi). Purity of enriched cells were >90%.  5xIJZ CD4+ T-cells were transferred 






TJ-X!3407459",4/;!b(KV(`!&K)%cA!!#9!9B4!4*+!68!8",4!+.;0=!54//0!@434!3409"2-/.94+ for 4 
hours with PMA (50ng/ml) and ionomycin (0.5ug/ml) in the presence of brefeldin A (10ug/ml) 
and 2ME (50uM) in DMEM-5% FBS.  Cells were surface stained, fixed in 4% paraformaldehyde 
for 20 minutes, and then permeabilized with 0.5% saponin in PBS.  Cells were then stained with 
anti-mouse IFN-!, IL-10, and T-bet antibodies (BD Biosciences) in 0.5% saponin.  Cells were 
treated with 10 ug/ml of anti-CD16/CD32 prior to antibody staining to prevent non-specific 
binding.  Specificity of intracellular cytokines was confirmed using unlabeled antibody as a cold 







CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
Why does this research matter?   
!
In response to the ongoing global impact of malaria, several large-scale organizations 
focus on reducing the presence of this disease.  The Roll Back Malaria program (RBM), initiated 
in 1998, started as a collaboration between the World Health Organization, UNICEF, UNDP, 
and the World Bank in order to coordinate their efforts to control malaria worldwide.  RBM 
efforts focus on vector intervention such as physical barriers (i.e. net tents) and mosquito 
population control (insecticides).  In addition, RBM  focuses on providing accessible drug 
treatment for infected individuals. This varied approach to combat malaria likely facilitated an 
estimated 20% decrease in malaria-associated mortality for children under 5 years old (88).  
Although current approaches maximize currently available tools to combat malaria, the 
disease will likely continue to take its toll on world communities.  Vector intervention provides a 
break in the infectious cycle of malaria, however a community can still be at risk of infection if 
there is inconsistent use of appropriate physical barriers.  Furthermore, access to drug treatment 
has certainly increased due to targeted efforts to diminish the presence of malaria, yet there are 
still areas that the limited resources cannot reach.  Even with treatment, there is a risk of the 
parasite developing drug resistance.  Lastly, unless malaria is eradicated worldwide, reducing the 
prevalence of malaria may be detrimental long term, in the case of reemergence of the disease, 
due to the severe morbidity associated with non-immune individuals.   
People living in malaria endemic areas often become semi-immune:  resistant to disease, 
but not necessarily to the presence of parasite.  Semi-immunity suggests that the immune system 
is important for long-term protection and the ability to prime the body’s response to infection 
! [T!
with semi-immune characteristics may be a long term solution in the fight against malaria.  
Priming a semi-immune response to malaria would use the complex defenses of the body to 
diminish the effect of the parasite.  
Severe malarial anemia "0!409"2.94+!96!O"//!>49@44*!I]J=JJJ!.*+!][F=JJJ!5B"/+34*!
-*+43!9B4!.14!68!Y!4.5B!;4.3!bZYcA!The research presented in this dissertation focuses on the 
immunomodulatory component that is important in mitigating malaria associated anemia:  IL-10 
expressing CD4+ T-cells.   



















How does this dissertation contribute to the greater body of knowledge? 
The balance between pro-inflammatory and anti-inflammatory cytokines can affect 
disease outcome.  In human clinical studies, high ratios of the pro-inflammatory cytokines TNF-
" and IFN-! to low IL-10 levels correlated with greater anemia during malaria infection, but 
were unrelated to parasite burden [14,15,16,17,18]. A recent study found that an IL-10 promoter 
haplotype associated with increased circulating IL-10 was protective for severe malarial anemia 
[19]. These studies indicate that IL-10 helps to modulate the inflammatory response to the 
parasite, allowing pro-inflammatory cytokines to orchestrate control of parasitemia while 





Malaria-associated morbidity in murine models has been determined by various measures 
of disease including weight loss, hypothermia, and hypoglycemia, however, the effect of IL-10 
on anemia has not been clearly defined.  With data presented in this dissertation, we provide an 
explanation for malaria-associated anemia that pivots around Il-10 expressing Th1 cells.  The 
absence of IL-10, either systemic or in CD4+ T-cells, increase IFN-! levels in circulation as well 
as in T-cells.  We also provide a glimpse into the signals the upregulate IL-10 in Th1 cells, such 























































The big picture: potential applications 
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